These studies support the therapeutic strategy to enhance anti-tumor immunity by boosting CD4 CTLs, especially when CD8 T cells become dysfunctional, or tumor cells lack HLA-I/co-stimulatory molecules. This evidence concerns the gene CD8A and neoplasm.